Monoclonal ANTIbody-targeted CARBon nanobues against cancer View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2008-2011

FUNDING AMOUNT

2967008 EUR

ABSTRACT

ANTICARB attempts to exploit the advantages offered by a novel nanotechnology platform – carbon nanotubes – and apply them to a clinically established therapeutic modality – targeted antibody therapy – for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics. ANTICARB combines two emerging technologies, antibody and nanotube technology, in a way that will allow safe development of antibody-nanotube conjugates and explore their swift translation into a clinical oncology setting. By combining proven, clinically used, anti-cancer agents – antibodies – with a novel nanotechnology-based platform made of advanced nanomaterials, ANTICARB aims at enhancing the therapeutic potency of the antibody and establish a new paradigm for oncology therapeutics. The ability of carbon nanotube technology to transport antibodies into the tumor cell cytoplasm may lead to validation of specific intracellular targets for oncology. This objective will be reached by adopting a multidisciplinary approach and by bringing together expertise from the fields of drug delivery, molecular biology, chemistry, engineering, pharmacology and toxicology. The proposal capitalises on this industry-academia multidisciplinary and perfectly integrated team, whose expertise spans from advanced biotech to sophisticated nanotechnology. More... »

URL

http://cordis.europa.eu/project/rcn/86759_en.html

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2210", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "EUR", 
      "type": "MonetaryAmount", 
      "value": "2967008"
    }, 
    "description": "ANTICARB attempts to exploit the advantages offered by a novel nanotechnology platform \u2013 carbon nanotubes \u2013 and apply them to a clinically established therapeutic modality \u2013 targeted antibody therapy \u2013 for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics. ANTICARB combines two emerging technologies, antibody and nanotube technology, in a way that will allow safe development of antibody-nanotube conjugates and explore their swift translation into a clinical oncology setting. By combining proven, clinically used, anti-cancer agents \u2013 antibodies \u2013 with a novel nanotechnology-based platform made of advanced nanomaterials, ANTICARB aims at enhancing the therapeutic potency of the antibody and establish a new paradigm for oncology therapeutics. The ability of carbon nanotube technology to transport antibodies into the tumor cell cytoplasm may lead to validation of specific intracellular targets for oncology. This objective will be reached by adopting a multidisciplinary approach and by bringing together expertise from the fields of drug delivery, molecular biology, chemistry, engineering, pharmacology and toxicology. The proposal capitalises on this industry-academia multidisciplinary and perfectly integrated team, whose expertise spans from advanced biotech to sophisticated nanotechnology.", 
    "endDate": "2011-08-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.270680.b", 
      "type": "Organization"
    }, 
    "id": "sg:grant.3773714", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "3773714"
        ]
      }, 
      {
        "name": "cordis_id", 
        "type": "PropertyValue", 
        "value": [
          "86759"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "sophisticated nanotechnologies", 
      "antibodies", 
      "new paradigm", 
      "advanced biotech", 
      "proposal", 
      "drug delivery", 
      "oncology", 
      "therapeutic modalities", 
      "field", 
      "tumor cell cytoplasm", 
      "ANTICARB", 
      "industry-academia multidisciplinary", 
      "carbon", 
      "clinical oncology settings", 
      "carbon nanotubes", 
      "anti-cancer agents", 
      "cancer", 
      "antibody-nanotube conjugates", 
      "antibody therapy", 
      "multidisciplinary approach", 
      "platform", 
      "therapeutic potency", 
      "engineering", 
      "validation", 
      "molecular biology", 
      "monoclonal antibodies", 
      "toxicology", 
      "advantages", 
      "creation", 
      "expertise", 
      "technology", 
      "chemistry", 
      "pharmacology", 
      "ability", 
      "oncology therapeutics", 
      "OBJECTIVE", 
      "specific intracellular targets", 
      "ANTICARB attempts", 
      "advanced nanomaterials", 
      "nanotube technology", 
      "cancer therapeutics", 
      "safe development", 
      "novel nanotechnology platforms", 
      "integrated team", 
      "novel nanotechnology", 
      "hybrid nanotechnology", 
      "swift translation", 
      "CARBon nanobues", 
      "way"
    ], 
    "name": "Monoclonal ANTIbody-targeted CARBon nanobues against cancer", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.5133.4", 
        "type": "Organization"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.3773714"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T11:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/cordis_projects_2.xml.gz", 
    "startDate": "2008-03-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://cordis.europa.eu/project/rcn/86759_en.html"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.3773714'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.3773714'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.3773714'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.3773714'


 

This table displays all metadata directly associated to this object as RDF triples.

83 TRIPLES      19 PREDICATES      69 URIs      62 LITERALS      4 BLANK NODES

Subject Predicate Object
1 sg:grant.3773714 schema:about anzsrc-for:2210
2 schema:amount N66f302cb6aa04e5abda309ff46e8e70a
3 schema:description ANTICARB attempts to exploit the advantages offered by a novel nanotechnology platform – carbon nanotubes – and apply them to a clinically established therapeutic modality – targeted antibody therapy – for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics. ANTICARB combines two emerging technologies, antibody and nanotube technology, in a way that will allow safe development of antibody-nanotube conjugates and explore their swift translation into a clinical oncology setting. By combining proven, clinically used, anti-cancer agents – antibodies – with a novel nanotechnology-based platform made of advanced nanomaterials, ANTICARB aims at enhancing the therapeutic potency of the antibody and establish a new paradigm for oncology therapeutics. The ability of carbon nanotube technology to transport antibodies into the tumor cell cytoplasm may lead to validation of specific intracellular targets for oncology. This objective will be reached by adopting a multidisciplinary approach and by bringing together expertise from the fields of drug delivery, molecular biology, chemistry, engineering, pharmacology and toxicology. The proposal capitalises on this industry-academia multidisciplinary and perfectly integrated team, whose expertise spans from advanced biotech to sophisticated nanotechnology.
4 schema:endDate 2011-08-31T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.270680.b
6 schema:identifier Naa8082d5c393431bb0a596385e1fe65f
7 Nacff56838c084d87becc07884946fdf7
8 schema:inLanguage en
9 schema:keywords ANTICARB
10 ANTICARB attempts
11 CARBon nanobues
12 OBJECTIVE
13 ability
14 advanced biotech
15 advanced nanomaterials
16 advantages
17 anti-cancer agents
18 antibodies
19 antibody therapy
20 antibody-nanotube conjugates
21 cancer
22 cancer therapeutics
23 carbon
24 carbon nanotubes
25 chemistry
26 clinical oncology settings
27 creation
28 drug delivery
29 engineering
30 expertise
31 field
32 hybrid nanotechnology
33 industry-academia multidisciplinary
34 integrated team
35 molecular biology
36 monoclonal antibodies
37 multidisciplinary approach
38 nanotube technology
39 new paradigm
40 novel nanotechnology
41 novel nanotechnology platforms
42 oncology
43 oncology therapeutics
44 pharmacology
45 platform
46 proposal
47 safe development
48 sophisticated nanotechnologies
49 specific intracellular targets
50 swift translation
51 technology
52 therapeutic modalities
53 therapeutic potency
54 toxicology
55 tumor cell cytoplasm
56 validation
57 way
58 schema:name Monoclonal ANTIbody-targeted CARBon nanobues against cancer
59 schema:recipient https://www.grid.ac/institutes/grid.5133.4
60 schema:sameAs https://app.dimensions.ai/details/grant/grant.3773714
61 schema:sdDatePublished 2019-03-07T11:22
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher N68fdaaedd634446a9627c78eaeab7f81
64 schema:startDate 2008-03-01T00:00:00Z
65 schema:url http://cordis.europa.eu/project/rcn/86759_en.html
66 sgo:license sg:explorer/license/
67 sgo:sdDataset grants
68 rdf:type schema:MonetaryGrant
69 N66f302cb6aa04e5abda309ff46e8e70a schema:currency EUR
70 schema:value 2967008
71 rdf:type schema:MonetaryAmount
72 N68fdaaedd634446a9627c78eaeab7f81 schema:name Springer Nature - SN SciGraph project
73 rdf:type schema:Organization
74 Naa8082d5c393431bb0a596385e1fe65f schema:name cordis_id
75 schema:value 86759
76 rdf:type schema:PropertyValue
77 Nacff56838c084d87becc07884946fdf7 schema:name dimensions_id
78 schema:value 3773714
79 rdf:type schema:PropertyValue
80 anzsrc-for:2210 schema:inDefinedTermSet anzsrc-for:
81 rdf:type schema:DefinedTerm
82 https://www.grid.ac/institutes/grid.270680.b schema:Organization
83 https://www.grid.ac/institutes/grid.5133.4 schema:Organization
 




Preview window. Press ESC to close (or click here)


...